KROS

10.06

0.79% -0.08

Dopo l'orario di chiusura: 10.06

Keros Therapeutics Inc (KROS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché KROS Giù? Forum Previsione

Precedente Chiudi:

$10.14

Aprire:

$10.36

Volume 24 ore:

140.63K

Relative Volume:

0.48

Capitalizzazione di mercato:

$199.11M

Reddito:

$33.18M

Utile/perdita netta:

$-85.15M

Rapporto P/E:

-3.3473

EPS:

-3.0054

Flusso di cassa netto:

$-58.25M

1 W Prestazione:

-5.45%

1M Prestazione:

-7.88%

6M Prestazione:

-47.60%

1 anno Prestazione:

-30.04%

Intervallo 1D:

$10.02

$10.36

Intervallo di 1 settimana:

$9.915

$10.97

Portata 52W:

$9.69

$22.55

Keros Therapeutics Inc Stock (KROS) Company Profile

Nome

Keros Therapeutics Inc

Settore

Healthcare (1071)

Industria

Biotechnology (598)

Telefono

617-314-6297

Indirizzo

1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-05

Ultimi documenti SEC

KROS's Discussions on Twitter

Compare KROS vs VRTX, REGN, ARGX, RVMD, ALNY

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
KROS Keros Therapeutics Inc	10.06	199.11M	33.18M	-85.15M	-58.25M	-3.0054
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-10-20	Iniziato	Wells Fargo	Overweight
2025-06-10	Downgrade	BofA Securities	Buy → Neutral
2025-01-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2025-01-17	Downgrade	Wedbush	Outperform → Neutral
2024-12-16	Downgrade	Guggenheim	Buy → Neutral
2024-12-16	Reiterato	Oppenheimer	Outperform
2024-12-13	Reiterato	H.C. Wainwright	Buy
2024-12-12	Downgrade	BTIG Research	Buy → Neutral
2024-12-12	Downgrade	TD Cowen	Buy → Hold
2024-12-12	Downgrade	William Blair	Outperform → Mkt Perform
2024-11-05	Iniziato	Jefferies	Buy
2024-10-24	Iniziato	Cantor Fitzgerald	Overweight
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-09-23	Iniziato	Guggenheim	Buy
2024-06-25	Iniziato	Oppenheimer	Outperform
2024-02-21	Iniziato	William Blair	Outperform
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-07-31	Iniziato	Wedbush	Outperform
2023-07-26	Iniziato	BofA Securities	Buy
2023-02-14	Iniziato	Cowen	Outperform
2022-10-18	Iniziato	Truist	Buy
2022-07-26	Iniziato	BTIG Research	Buy
2020-12-08	Reiterato	H.C. Wainwright	Buy
2020-05-04	Iniziato	H.C. Wainwright	Buy
2020-05-04	Iniziato	Jefferies	Buy
2020-05-04	Iniziato	Piper Sandler	Overweight
2020-05-04	Iniziato	SVB Leerink	Outperform

Mostra tutto

Keros Therapeutics Inc Borsa (KROS) Ultime notizie

04:59 AM

Keros Therapeutics (NASDAQ: KROS) names interim finance and accounting head - Stock Titan

Jul 22, 2026

Discipline and Rules-Based Execution in KROS Response - Stock Traders Daily

Jul 22, 2026

Keros Therapeutics CFO Keith Regnante resigns effective Aug. 3 - scanx.trade

Jul 22, 2026

Jul 20, 2026

KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - qz.com

Jul 20, 2026

Keros Therapeutics (KROS) Holds Steady Near Support LevelUp Down Volume - dars.gov.et

Jul 20, 2026

Jul 17, 2026

Keros Therapeutics (KROS) director adds 1,000 shares under 10b5-1 plan - Stock Titan

Jul 17, 2026

BlackRock Portfolio Management (KROS) discloses 5.7% ownership in Keros Therapeutics - Stock Titan

Jul 17, 2026

Insiders Sold Keros Therapeutics Prematurely At US$15.15 With Stock Trading Higher - simplywall.st

Jul 17, 2026

Nurix Therapeutics (NRIX) soars 16.4%: Is further upside left in the stock? - MSN

Jul 17, 2026

Jul 16, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Jul 16, 2026

Jul 10, 2026

KROS Q1 2026 Earnings: Wider-than-Expected Loss as Clinical Progress ContinuesEPS Growth Rate - dars.gov.et

Jul 10, 2026

Jul 07, 2026

KROS Q1 2026 Earnings: EPS Miss of 15.98% as Clinical-Stage Biotech Reports Wider-Than-Expected LossProfit Announcement - dars.gov.et

Jul 07, 2026

Keros Therapeutics | DEFA14A: Others - Moomoo

Jul 07, 2026

Jul 06, 2026

Form 4 Keros Therapeutics Inc For: 6 July By Investing.com - Investing.com Nigeria

Jul 06, 2026

Keros Therapeutics (KROS) grants director Anne Prener RSUs and stock options - Stock Titan

Jul 06, 2026

Director Anne Prener files Form 3 insider report at Keros Therapeutics (KROS) - Stock Titan

Jul 06, 2026

Jul 02, 2026

Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors - TipRanks

Jul 02, 2026

Jul 01, 2026

KROS Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineProfit Inflection Point - dars.gov.et

Jul 01, 2026

Jun 29, 2026

Behavioral Patterns of KROS and Institutional Flows - Stock Traders Daily

Jun 29, 2026

Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Value-Defensive Index - marketscreener.com

Jun 28, 2026

Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Defensive Index - marketscreener.com

Jun 28, 2026

Jun 27, 2026